Restricted mean survival time as a summary measure of time‐to‐event outcome-Reference-Cited by-同舟云学术

Restricted mean survival time as a summary measure of time‐to‐event outcome

Published:2020-02-18 Issue:4 Volume:19 Page:436-453
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Hasegawa Takahiro¹^ORCID,Misawa Saori²,Nakagawa Shintaro³,Tanaka Shinichi⁴,Tanase Takanori⁵^ORCID,Ugai Hiroyuki⁶,Wakana Akira⁷,Yodo Yasuhide⁸,Tsuchiya Satoru⁸,Suganami Hideki⁹,

Affiliation:

1. Biostatistics CenterShionogi & Co, Ltd Osaka Japan

2. Clinical Development Strategy Department, Pharmaceutical Development Division, Nippon Kayaku Co, Ltd Tokyo Japan

3. Clinical Information & Intelligence Department, Chugai Pharmaceutical Co, Ltd Tokyo Japan

4. Biostatistics & Data Management Department, Clinical Development Division, Nippon Shinyaku Co, Ltd Kyoto Japan

5. Data Science DepartmentTaiho Pharmaceutical Co, Ltd Tokyo Japan

6. Biostatistics & Data Science, Nippon Boehringer Ingelheim Co, Ltd Tokyo Japan

7. Biostatistics and Research Decision Sciences, Japan Development, MSD K.K. Tokyo Japan

8. Data Science, Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd. Tokyo Japan

9. Clinical Data Science Department, Kowa Company, Ltd Nagoya Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2004

Reference50 articles.

1. Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

2. The PMDAWebsite (in Japanese). (Available at:https://www.pmda.go.jp/files/000221609.pdf) [accessed on January 15 2020].

3. Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

5. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method;BMC Medical Research Methodology;2024-07-30

2. Competing Risks and Multistate Modelsin Oncology Clinical Trials;Japanese Journal of Biometrics;2024-07-30

3. Robust and Interpretable Hazard-based Summary Measures of the Magnitude of the Treatment Effect and Their Inference Procedures;Japanese Journal of Biometrics;2024-07-30

4. Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study;Pulmonology;2024-04

5. Simultaneous inference procedures for the comparison of multiple characteristics of two survival functions;Statistical Methods in Medical Research;2024-03-11